Edwards Lifesciences Valuation
Is EWL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Por debajo del valor justo
Muy por debajo del valor justo
Price-To-Earnings vs. similares
Price-To-Earnings vs. Industria
PM vs. Ratio Justo
Pronóstico de los analistas
Share Price vs Fair Value
What is the Fair Price of EWL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Por debajo del valor justo: EWL (€83.9) cotiza por debajo de nuestra estimación de valor razonable (€84.67)
Muy por debajo del valor justo: EWL se negocia por debajo de su valor razonable, pero no por un importe significativo.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EWL?
Other financial metrics that can be useful for relative valuation.
| What is EWL's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$55.80b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 9.1x |
| Enterprise Value/EBITDA | 29.3x |
| PEG Ratio | 4.3x |
Price to Earnings Ratio vs Peers
How does EWL's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 27.5x | ||
SHL Siemens Healthineers | 40.8x | 19.5% | €61.9b |
AFX Carl Zeiss Meditec | 34.5x | 11.7% | €9.6b |
DRW3 Drägerwerk KGaA | 8.9x | 5.8% | €914.6m |
EUZ Eckert & Ziegler | 25.6x | 9.2% | €767.7m |
EWL Edwards Lifesciences | 39.6x | 9.1% | €55.8b |
Price-To-Earnings vs. similares: EWL es caro según su Ratio Price-To-Earnings (37.3x) en comparación con la media de sus homólogos (29x).
Price to Earnings Ratio vs Industry
How does EWL's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs. Industria: EWL es caro en función de su Ratio Price-To-Earnings (37.3x) en comparación con la media del sector European Medical Equipment (35.2x).
Price to Earnings Ratio vs Fair Ratio
What is EWL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 39.6x |
| Fair PE Ratio | 39.2x |
PM vs. Ratio Justo: EWL es caro en función de su Ratio Price-To-Earnings (39.1x) comparado con el Ratio Price-To-Earnings estimado (39.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €84.99 | €85.81 +1.0% | 9.1% | €96.72 | €66.32 | n/a | 28 |
| Apr ’25 | €88.92 | €85.85 -3.5% | 9.2% | €97.34 | €66.74 | n/a | 28 |
| Mar ’25 | €78.60 | €84.46 +7.5% | 8.3% | €97.15 | €66.61 | n/a | 28 |
| Feb ’25 | €74.00 | €73.64 -0.5% | 12.3% | €88.32 | €52.44 | n/a | 28 |
| Jan ’25 | €69.00 | €72.36 +4.9% | 12.3% | €87.25 | €51.81 | n/a | 28 |
| Dec ’24 | €62.44 | €73.02 +16.9% | 14.4% | €92.85 | €51.89 | n/a | 28 |
| Nov ’24 | €59.44 | €77.07 +29.7% | 13.8% | €96.52 | €59.62 | n/a | 27 |
| Oct ’24 | €65.90 | €90.48 +37.3% | 8.8% | €104.05 | €70.94 | n/a | 26 |
| Sep ’24 | €70.30 | €87.49 +24.4% | 8.8% | €100.16 | €68.29 | n/a | 24 |
| Aug ’24 | €74.78 | €87.49 +17.0% | 8.8% | €100.16 | €68.29 | n/a | 24 |
| Jul ’24 | €86.28 | €87.06 +0.9% | 8.5% | €97.59 | €67.85 | n/a | 23 |
| Jun ’24 | €78.52 | €87.06 +10.9% | 8.5% | €97.59 | €67.85 | n/a | 23 |
| May ’24 | €79.00 | €84.15 +6.5% | 8.7% | €95.29 | €66.25 | n/a | 22 |
| Apr ’24 | €76.09 | €80.09 +5.3% | 9.6% | €92.25 | €61.81 | €88.92 | 22 |
| Mar ’24 | €74.00 | €83.62 +13.0% | 13.5% | €121.10 | €62.41 | €78.60 | 22 |
| Feb ’24 | €71.25 | €80.64 +13.2% | 14.1% | €118.34 | €60.08 | €74.00 | 22 |
| Jan ’24 | €70.10 | €85.99 +22.7% | 16.0% | €122.43 | €64.04 | €69.00 | 23 |
| Dec ’23 | €74.53 | €90.55 +21.5% | 13.8% | €123.50 | €69.35 | €62.44 | 22 |
| Nov ’23 | €72.73 | €96.83 +33.1% | 13.4% | €130.47 | €78.28 | €59.44 | 23 |
| Oct ’23 | €84.88 | €117.51 +38.4% | 9.3% | €132.09 | €94.50 | €65.90 | 20 |
| Sep ’23 | €89.48 | €115.74 +29.3% | 9.6% | €134.41 | €92.59 | €70.30 | 20 |
| Aug ’23 | €97.42 | €113.84 +16.9% | 9.3% | €132.17 | €91.05 | €74.78 | 21 |
| Jul ’23 | €89.61 | €119.00 +32.8% | 10.8% | €133.99 | €91.88 | €86.28 | 21 |
| Jun ’23 | €94.06 | €120.30 +27.9% | 10.3% | €133.77 | €91.73 | €78.52 | 21 |
| May ’23 | €104.16 | €122.15 +17.3% | 9.5% | €136.54 | €91.03 | €79.00 | 23 |
| Apr ’23 | €106.80 | €117.07 +9.6% | 9.9% | €131.05 | €87.37 | €76.09 | 22 |
Pronóstico de los analistas: El precio objetivo es inferior a 20% superior al precio actual de la acción.